Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine, quantity: 3 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (wolff-parkinson-white syndrome). diagnostic indications: aid to diagnosis of broad or narrow complex supraventricular tachycardias. although adenocor is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be only used when, despite all diagnostic attempts, doubt still persists. improved diagnostic sensitivity of intracavity electrophysiological investigations

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; lactose monohydrate; hyprolose; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; propylene glycol; titanium dioxide; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; sodium lauryl sulfate; hyprolose; magnesium stearate; lactose monohydrate; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; crospovidone - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; propylene glycol; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; crospovidone; hyprolose; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium lauryl sulfate; hypromellose; titanium dioxide; crospovidone; propylene glycol; lactose monohydrate; iron oxide red; microcrystalline cellulose; iron oxide yellow; hyprolose - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 0.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; propylene glycol; crospovidone; titanium dioxide; hyprolose; lactose monohydrate; sodium lauryl sulfate - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ademetionine - oral tablet - 200mg

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

corteva agriscience australia pty ltd - cloquintocet acid; pyroxsulam - water dispersible granule - cloquintocet acid acid active 451.5 g/kg; pyroxsulam sulfonamide active 215.0 g/kg - herbicide

США - англійська - NLM (National Library of Medicine)

meda pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - demadex is indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. demadex is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with demadex. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educ

США - англійська - NLM (National Library of Medicine)

roche pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - tablet - 5 mg - demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. demadex intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. demadex is contraindicated in patients with known hypersensitivity to demadex or to sulfonylureas. demadex is contraindicated in patients who are anuric.